U.S. markets open in 6 hours 51 minutes

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
73.27+0.09 (+0.12%)
At close: 4:00PM EST

Novo Nordisk A/S

Novo Allé
Bagsvaerd 2880
45 44 44 88 88

Full Time Employees44,326

Key Executives

NameTitlePayExercisedYear Born
Mr. Lars Fruergaard JørgensenPres, CEO & Member of Management BoardN/AN/A1966
Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management BoardN/AN/A1971
Dr. Mads Krogsgaard ThomsenExec. VP, Chief Scientific Officer, Head of R&D and Member of the Management BoardN/AN/A1960
Mr. Henrik Ehlers WulffExec. VP, Head of Product Supply, Quality & IT and Member of the Management BoardN/AN/A1970
Ms. Camilla SylvestExec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management BoardN/AN/A1972
Ms. Monique CarterExec. VP, Head of People & Organisation and Member of Management BoardN/AN/A1973
Mr. Maziar Mike DoustdarExec. VP, Head of International Operations & Member of the Management BoardN/AN/A1970
Mr. Douglas J. LangaExec. VP, Head of North America Operations & Member of Management BoardN/AN/A1966
Mr. Ludovic HelfgottExec. VP, Head of Biopharm & Member of Management BoardN/AN/A1974
Mr. Peter Hugreffe AnkersenHead of Investor Relations & Corp. VPN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate Governance

Novo Nordisk A/S’s ISS Governance QualityScore as of January 22, 2021 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 10; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.